Phase 3 Readout
TGTX: Phase 3 Topline: A Multicenter, Randomized, Double-blind, Placebo-controlled Phase IIb/III Study to Assess the Effica
July 30, 2026. BioSniper AI can trace the company-impact path without requiring you to write the research question.
- Event date
- July 30, 2026
- Company
- TG THERAPEUTICS, INC. (TGTX)
BioSniper AIPage evidence connected
Prepared research question
What could this event change, and which evidence should be watched next?
Run cited research
Traceable citations · Unknowns marked
Phase 3 Readout~month
Phase 3 Topline: A Multicenter, Randomized, Double-blind, Placebo-controlled Phase IIb/III Study to Assess the Effica
- Company
- TG THERAPEUTICS, INC. (TGTX)
- Indication
- Seasonal Allergic Rhinitis; SAR